CAMK2G and myocardial infarction: We used recently validated phospho-specific antibodies against MCU (pMCU)32, predicted CaMKII phosphorylation sites, and found an increase in phosphorylation of this CaMKII target in mitochondria from hearts after MI compared to sham-operated hearts (Fig. 1a, b).